Experiences of patients resuming life after immunotherapy for metastatic melanoma

نویسندگان

چکیده

Abstract Linked Article: Kamminga et al. Br J Dermatol 2022; 187:381–391.

برای دانلود باید عضویت طلایی داشته باشید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Complications of sequential immunotherapy in metastatic melanoma

Background Advanced melanoma is associated with a poor prognosis. Targeted therapy and immunotherapy are mainstays of treatment. High-dose interleukin-2 (HD IL-2), interferon alfa-2b, cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitors, and programmed cell death protein 1 (PD-1) inhibitors are approved immunotherapies. Genetically engineered T cells targeting melanoma antigens are c...

متن کامل

Non-metastatic Non-melanoma Skin Cancers: Our 3 Years of Clinical Experiences

BACKGROUND Nonmelanoma skin cancers (NMSC) constitute the largest group of skin cancers. In this study, NMSCs were analyzed retrospectively. METHODS Between June 2013 and March 2017, demographics and comorbidities of patients underwent reconstructive surgery for NMSC; their risk factors, types, diameters, differentiation, localizations, follow-up times, treatment methods and complications we...

متن کامل

Quality of life in Croatian metastatic melanoma patients.

The aim of this study was to examine the quality of life (QoL) in 40 Croatian metastatic melanoma patients who had completed at least first-line treatment and to see if there was a correlation between QoL parameters and serum lactate dehydrogenase (LDH). LDH levels were measured and all patients clinically examined between April and September 2013. Two QoL questionnaires were used for patient s...

متن کامل

Intrathecal Cytotoxic T-Cell Immunotherapy for Metastatic Leptomeningeal Melanoma

A 49-year-old patient with primary, recurrent melanoma on the lower extremity developed metastatic leptomeningeal melanoma that did not respond to treatment with radiation therapy or intrathecal interleukin 2 (IL-2). Disease was characterized by neurological symptoms, including loss of hearing, loss of short-term memory, and gait disturbance. CD8 + CTLs were generated in vitro using autologous ...

متن کامل

Current status and perspectives in immunotherapy for metastatic melanoma

Metastatic melanoma was the first malignancy in which immune checkpoint inhibitors demonstrated their successful efficacy. Currently, the knowledge on the interaction between the immune system and malignant disease is steadily increasing and new drugs and therapeutic strategies are overlooking in the clinical scenario. To provide a comprehensive overview of immune modulating drugs currently ava...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

ژورنال

عنوان ژورنال: British Journal of Dermatology

سال: 2022

ISSN: ['1365-2133', '0007-0963']

DOI: https://doi.org/10.1111/bjd.21733